Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción ABP?
El precio actual de ABP es de $0.2181, ha increased un 9.04% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de ABPRO Holdings Inc?
ABPRO Holdings Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de ABPRO Holdings Inc?
La capitalización bursátil actual de ABPRO Holdings Inc es $17.4M
¿Es ABPRO Holdings Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 2 analistas han realizado calificaciones de análisis para ABPRO Holdings Inc, incluyendo 1 fuerte compra, 3 compra, 1 mantener, 0 venta, y 1 fuerte venta
